Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG

Sangeetha Iyer, Ethan Perlstein
bioRxiv (Cold Spring Harbor Laboratory)
May 3, 2019
10.1101/626697
Cited by 32

Related Papers

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
|Disease Models & Mechanisms|2019|78
Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic Implications
|Annals of Neurology|2021|57